ADMA
ADMA Biologics, Inc.
Biotechnology
Market Cap$1.89B
5Y Perf.+148.3%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ADMA vs HALO vs ALNY vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
HALO
Halozyme Therapeutics, Inc.
Biotechnology
Market Cap$7.55B
5Y Perf.+164.2%
ALNY
Alnylam Pharmaceuticals, Inc.
Biotechnology
Market Cap$39.37B
5Y Perf.+118.1%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
ADMA vs HALO vs ALNY vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ADMA | HALO | ALNY | RARE |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $1.89B | $7.55B | $39.37B | $2.57B |
| Revenue (TTM) | $510M | $1.40B | $4.29B | $669M |
| Net Income (TTM) | $165M | $317M | $577M | $-609M |
| Gross Margin | 61.3% | 81.9% | 80.9% | 83.6% |
| Operating Margin | 42.1% | 58.4% | 17.5% | -83.9% |
| Forward P/E | 9.7x | 8.0x | 39.9x | — |
| Total Debt | $80M | $0.00 | $1.28B | $1.28B |
| Cash & Equiv. | $88M | $134M | $1.66B | $434M |
ADMA vs HALO vs ALNY vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ADMA
HALO
ALNY
RARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | 100 | 248.3 | +148.3% |
| Halozyme Therapeuti… (HALO) | 100 | 264.2 | +164.2% |
| Alnylam Pharmaceuti… (ALNY) | 100 | 218.1 | +118.1% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ADMA vs HALO vs ALNY vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ADMA and HALO are tied at the top with 2 categories each — the right choice depends on your priorities. Halozyme Therapeutics, Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. ALNY also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ADMA
ADMA Biologics, Inc.
The Income Pick
ADMA has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 1.25
- Lower volatility, beta 1.25, Low D/E 16.7%, current ratio 6.71x
- 32.4% margin vs RARE's -91.0%
- 27.4% ROA vs RARE's -45.8%, ROIC 36.0% vs -89.4%
Best for: income & stability and sleep-well-at-night
HALO
Halozyme Therapeutics, Inc.
The Long-Run Compounder
HALO is the #2 pick in this set and the best alternative if long-term compounding and defensive is your priority.
- 5.6% 10Y total return vs ALNY's 410.4%
- Beta 0.51, current ratio 4.66x
- Better valuation composite
- Beta 0.51 vs RARE's 1.36
Best for: long-term compounding and defensive
ALNY
Alnylam Pharmaceuticals, Inc.
The Growth Play
ALNY is the clearest fit if your priority is growth exposure.
- Rev growth 65.2%, EPS growth 206.9%, 3Y rev CAGR 53.0%
- 65.2% revenue growth vs ADMA's 19.6%
- +14.2% vs ADMA's -61.5%
Best for: growth exposure
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ALNY | 65.2% revenue growth vs ADMA's 19.6% |
| Value | HALO | Better valuation composite |
| Quality / Margins | ADMA | 32.4% margin vs RARE's -91.0% |
| Stability / Safety | HALO | Beta 0.51 vs RARE's 1.36 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | ALNY | +14.2% vs ADMA's -61.5% |
| Efficiency (ROA) | ADMA | 27.4% ROA vs RARE's -45.8%, ROIC 36.0% vs -89.4% |
ADMA vs HALO vs ALNY vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
FY 2025
FY 2025
ADMA vs HALO vs ALNY vs RARE — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLADMALAGGINGRARE
Who Leads Where
HALO leads in 2 of 6 categories
ADMA leads 2 • ALNY leads 0 • RARE leads 0 • 1 tied
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
ALNYAlnylam Pharmaceutica…
0leads
HALOHalozyme Therapeutics…
2leads
ADMAADMA Biologics, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs HALOvs ALNYMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
HALO3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ADMA4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ADMA3/6
Risk & VolatilityBeta, volatility, and downside exposure
HALO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — HALO and ALNY each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALNY is the larger business by revenue, generating $4.3B annually — 8.4x ADMA's $510M. ADMA is the more profitable business, keeping 32.4% of every revenue dollar as net income compared to RARE's -91.0%. On growth, ALNY holds the edge at +96.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ADMAADMA Biologics, I… | HALOHalozyme Therapeu… | ALNYAlnylam Pharmaceu… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $510M | $1.4B | $4.3B | $669M |
| EBITDAEarnings before interest/tax | $221M | $945M | $677M | -$536M |
| Net IncomeAfter-tax profit | $165M | $317M | $577M | -$609M |
| Free Cash FlowCash after capex | $108M | $645M | $641M | -$487M |
| Gross MarginGross profit ÷ Revenue | +61.3% | +81.9% | +80.9% | +83.6% |
| Operating MarginEBIT ÷ Revenue | +42.1% | +58.4% | +17.5% | -83.9% |
| Net MarginNet income ÷ Revenue | +32.4% | +22.7% | +13.5% | -91.0% |
| FCF MarginFCF ÷ Revenue | +21.2% | +46.2% | +15.0% | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -0.3% | +51.6% | +96.4% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +72.7% | -2.1% | +4.4% | -17.2% |
Evenly matched — HALO and ALNY each lead in 2 of 6 comparable metrics.
Valuation Metrics
HALO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 13.6x trailing earnings, ADMA trades at a 89% valuation discount to ALNY's 126.6x P/E. On an enterprise value basis, HALO's 8.2x EV/EBITDA is more attractive than ALNY's 70.0x.
| Metric | ADMAADMA Biologics, I… | HALOHalozyme Therapeu… | ALNYAlnylam Pharmaceu… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Market CapShares × price | $1.9B | $7.6B | $39.4B | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $1.9B | $7.4B | $39.0B | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | 13.62x | 25.05x | 126.63x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.69x | 7.96x | 39.92x | — |
| PEG RatioP/E ÷ EPS growth rate | — | 1.09x | — | — |
| EV / EBITDAEnterprise value multiple | 9.45x | 8.20x | 69.97x | — |
| Price / SalesMarket cap ÷ Revenue | 3.71x | 5.41x | 10.60x | 3.82x |
| Price / BookPrice ÷ Book value/share | 4.19x | 162.76x | 50.35x | — |
| Price / FCFMarket cap ÷ FCF | 68.06x | 11.72x | 84.59x | — |
HALO leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
ADMA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
HALO delivers a 6.5% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-6 for RARE. ADMA carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALNY's 1.62x. On the Piotroski fundamental quality scale (0–9), ALNY scores 6/9 vs RARE's 4/9, reflecting solid financial health.
| Metric | ADMAADMA Biologics, I… | HALOHalozyme Therapeu… | ALNYAlnylam Pharmaceu… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +39.0% | +6.5% | +98.3% | -6.1% |
| ROA (TTM)Return on assets | +27.4% | +12.5% | +11.8% | -45.8% |
| ROICReturn on invested capital | +36.0% | +73.4% | +33.4% | -89.4% |
| ROCEReturn on capital employed | +38.8% | +38.2% | +15.3% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.17x | — | 1.62x | — |
| Net DebtTotal debt minus cash | -$8M | -$134M | -$379M | $842M |
| Cash & Equiv.Liquid assets | $88M | $134M | $1.7B | $434M |
| Total DebtShort + long-term debt | $80M | $0 | $1.3B | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | 50.85x | 46.08x | 2.02x | -14.49x |
ADMA leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ADMA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ADMA five years ago would be worth $48,922 today (with dividends reinvested), compared to $2,391 for RARE. Over the past 12 months, ALNY leads with a +14.2% total return vs ADMA's -61.5%. The 3-year compound annual growth rate (CAGR) favors ADMA at 32.7% vs RARE's -17.8% — a key indicator of consistent wealth creation.
| Metric | ADMAADMA Biologics, I… | HALOHalozyme Therapeu… | ALNYAlnylam Pharmaceu… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -54.3% | -8.8% | -26.3% | +10.7% |
| 1-Year ReturnPast 12 months | -61.5% | -5.3% | +14.2% | -27.4% |
| 3-Year ReturnCumulative with dividends | +133.4% | +111.8% | +40.5% | -44.5% |
| 5-Year ReturnCumulative with dividends | +389.2% | +39.1% | +129.4% | -76.1% |
| 10-Year ReturnCumulative with dividends | +34.8% | +559.7% | +410.4% | -59.4% |
| CAGR (3Y)Annualised 3-year return | +32.7% | +28.4% | +12.0% | -17.8% |
ADMA leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
HALO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HALO is the less volatile stock with a 0.51 beta — it tends to amplify market swings less than RARE's 1.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HALO currently trades 78.0% from its 52-week high vs ADMA's 35.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ADMAADMA Biologics, I… | HALOHalozyme Therapeu… | ALNYAlnylam Pharmaceu… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.25x | 0.51x | 0.74x | 1.36x |
| 52-Week HighHighest price in past year | $22.73 | $82.22 | $495.55 | $42.37 |
| 52-Week LowLowest price in past year | $7.21 | $47.50 | $245.96 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +35.9% | +78.0% | +59.5% | +61.6% |
| RSI (14)Momentum oscillator 0–100 | 26.0 | 47.7 | 39.9 | 67.7 |
| Avg Volume (50D)Average daily shares traded | 7.4M | 1.4M | 1.1M | 1.8M |
HALO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ADMA as "Buy", HALO as "Buy", ALNY as "Buy", RARE as "Buy". Consensus price targets imply 157.0% upside for ADMA (target: $21) vs 17.9% for HALO (target: $76).
| Metric | ADMAADMA Biologics, I… | HALOHalozyme Therapeu… | ALNYAlnylam Pharmaceu… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $21.00 | $75.60 | $445.67 | $48.36 |
| # AnalystsCovering analysts | 10 | 27 | 52 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.7% | +4.5% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
HALO leads in 2 of 6 categories (Valuation Metrics, Risk & Volatility). ADMA leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallADMA Biologics, Inc. (ADMA)Leads 2 of 6 categories
Loading custom metrics...
ADMA vs HALO vs ALNY vs RARE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ADMA or HALO or ALNY or RARE a better buy right now?
For growth investors, Alnylam Pharmaceuticals, Inc.
(ALNY) is the stronger pick with 65. 2% revenue growth year-over-year, versus 19. 6% for ADMA Biologics, Inc. (ADMA). ADMA Biologics, Inc. (ADMA) offers the better valuation at 13. 6x trailing P/E (9. 7x forward), making it the more compelling value choice. Analysts rate ADMA Biologics, Inc. (ADMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ADMA or HALO or ALNY or RARE?
On trailing P/E, ADMA Biologics, Inc.
(ADMA) is the cheapest at 13. 6x versus Alnylam Pharmaceuticals, Inc. at 126. 6x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — ADMA or HALO or ALNY or RARE?
Over the past 5 years, ADMA Biologics, Inc.
(ADMA) delivered a total return of +389. 2%, compared to -76. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: HALO returned +559. 7% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ADMA or HALO or ALNY or RARE?
By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.
(HALO) is the lower-risk stock at 0. 51β versus Ultragenyx Pharmaceutical Inc. 's 1. 36β — meaning RARE is approximately 166% more volatile than HALO relative to the S&P 500. On balance sheet safety, ADMA Biologics, Inc. (ADMA) carries a lower debt/equity ratio of 17% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ADMA or HALO or ALNY or RARE?
By revenue growth (latest reported year), Alnylam Pharmaceuticals, Inc.
(ALNY) is pulling ahead at 65. 2% versus 19. 6% for ADMA Biologics, Inc. (ADMA). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -25. 9% for ADMA Biologics, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ADMA or HALO or ALNY or RARE?
ADMA Biologics, Inc.
(ADMA) is the more profitable company, earning 28. 8% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -79. 5% for RARE. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ADMA or HALO or ALNY or RARE more undervalued right now?
On forward earnings alone, Halozyme Therapeutics, Inc.
(HALO) trades at 8. 0x forward P/E versus 39. 9x for Alnylam Pharmaceuticals, Inc. — 32. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADMA: 157. 0% to $21. 00.
08Which pays a better dividend — ADMA or HALO or ALNY or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is ADMA or HALO or ALNY or RARE better for a retirement portfolio?
For long-horizon retirement investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), +559. 7% 10Y return). Both have compounded well over 10 years (HALO: +559. 7%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ADMA and HALO and ALNY and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(ADMA: -0.3% · HALO: 51.6%)Net Margin>
%
(ADMA: 32.4% · HALO: 22.7%)P/E Ratio<
x
(ADMA: 13.6x · HALO: 25.0x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.